Clinical trials: Myeloma, Plasma-Cell
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID) in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy following second unplanned autologous peripheral…
- Trial name
- Immuno-POWER (NCT04584307)
- Testing
- Elotuzumab, Pomalidomide
- Sponsor
- Natalie Callendar
Multiple Myeloma
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02902965
- Testing
- Ibrutinib, Bortezomib, Dexamethasone
- Where
- 33 sites in Czechia, Germany and 4 more
- Volunteers
- 74 people
- Sponsor
- Pharmacyclics Switzerland GmbH
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- CARAMEL 2 (NCT01812720)
- Testing
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Lymphoma, Multiple Myeloma
Lonquek for Autologous Stem Cell Mobilization
The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous…
- Trial name
- NCT02488382
- Testing
- Lonquek
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Multiple Myeloma
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
The primary objective of this observational study is to identify the molecular profiles and clinical characteristics that define subsets of myeloma patients during the course of the disease.
- Trial name
- CoMMpass (NCT01454297)
- Where
- 73 sites in United States, Canada and 1 more
- Volunteers
- 1,154 people
- Sponsor
- Multiple Myeloma Research Foundation
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00317798
- Testing
- anti-thymocyte globulin, sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Multiple Myeloma
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00415064
- Testing
- Perifosine, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
The primary objective of this study is to document efficacy and safety data in a real-world setting of Chinese multiple myeloma patients who have received at least one prior therapy treated with REVLIMID (lenalidomide).
- Trial name
- NCT01947309
- Testing
- Revlimid (lenalidomide)
- Where
- 17 sites in China
- Volunteers
- 176 people
- Sponsor
- Celgene
Blood Cancer, Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body…
- Trial name
- NCT00185614
- Testing
- Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wen-Kai Weng
Recurrent Plasma Cell Myeloma
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
This phase I trial studies the side effects and best dose of R-(-)-gossypol acetic acid when given together with lenalidomide and dexamethasone and to see how well it works in treating patients with multiple myeloma, also known…
- Trial name
- NCT02697344
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Acute Kidney Injury, Multiple Myeloma
Biomarkers of AKI in Patients Receiving Daratumumab
The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with…
- Conditions
- Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
- Trial name
- NCT06549634
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Multiple Myeloma
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NIMBUS (NCT01311687)
- Testing
- pomalidomide, Dexamethasone
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 455 people
- Sponsor
- Celgene
Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing…
- Trial name
- NCT00431340
- Testing
- PXD101
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Valerio Therapeutics
Myelodysplastic Syndromes, Myeloproliferative Disorders
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Pre-transplant conditioning will include Fludarabine and dose-escalated Busulfan on days -6, -5, -4, and -3. Daily treatment doses will be adjusted to achieve target area under the plasma concentration time curve (AUC).
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Myeloma
- Trial name
- NCT00361140
- Testing
- Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib.
- Trial name
- NCT02148913
- Testing
- Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Corewell Health West
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in older adults or younger infirm patients with high-risk hematopoeitic malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00513318
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL)
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the…
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
- Trial name
- NCT02920697
- Testing
- S 55746
- Where
- 18 sites in Australia, France and 6 more
- Volunteers
- 65 people
- Sponsor
- Institut de Recherches Internationales Servier
Multiple Myeloma
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
- Trial name
- NCT00153920
- Testing
- bortezomib
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Study of ODX (OsteoDex) in Multiple Myeloma
The current phase I/IIa trial is a multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX. Each dose cohort will consist of 4 subjects.
- Trial name
- NCT06616389
- Testing
- ODX (Osteodex)
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- DexTech Medical AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.